Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 4/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19851192 | 0.88 | OPRL1 (0.42) | OPRL1OPRM1OPRD1OPRK1CYP2D6 | |
| SCHEMBL19851211 | 0.87 | OPRL1 (0.44) | OPRL1OPRM1OPRD1OPRK1TSHR | |
| SCHEMBL19851178 | 0.86 | OPRL1 (0.49) | OPRL1OPRM1OPRD1OPRK1CYP2D6 | |
| SCHEMBL19839177 | 0.86 | OPRL1 (0.49) | OPRL1OPRM1OPRD1OPRK1CYP2D6 | |
| SCHEMBL25311909 | 0.84 | OPRL1 (0.42) | OPRL1OPRM1OPRD1OPRK1CYP2D6 | |
| SCHEMBL1555927 | 0.82 | SLC6A9 (0.50) | OPRL1OPRM1OPRD1OPRK1CYP2D6 | |
| SCHEMBL21104902 | 0.82 | CYP2D6 (0.46) | OPRL1OPRM1OPRD1OPRK1CYP2D6 | |
| SCHEMBL25875252 | 0.82 | CYP2D6 (0.46) | OPRL1OPRM1OPRD1OPRK1CYP2D6 | |
| SCHEMBL25875253 | 0.82 | CYP2D6 (0.46) | OPRL1OPRM1OPRD1OPRK1CYP2D6 | |
| SCHEMBL25312897 | 0.81 | RAB9A (0.42) | OPRL1OPRM1OPRD1OPRK1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210851-A1 | SPIRO-LACTAM COMPOUNDS AND METHODS OF TREATING VIRAL INFECTIONS USING THE SAME | APTINYX INC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230210851-A1 | SPIRO-LACTAM COMPOUNDS AND METHODS OF TREATING VIRAL INFECTIONS USING THE SAME | APTINYX INC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230131402-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230131402-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-20220273629-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH ELEVATED LEVELS OF ANTIBODIES THAT INTERACT WITH THE NMDA RECEPTOR | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2022-09-01 | — | — | US | disclosed |
| US-11376250-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210322406-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2021-10-21 | — | — | US | disclosed |
| US-10918637-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2021-02-16 | — | — | US | disclosed |
| WO-2021021996-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH ELEVATED LEVELS OF ANTIBODIES THAT INTERACT WITH THE NMDA RECEPTOR | APTINYX INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| US-20190175588-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2019-06-13 | — | — | US | disclosed |
| WO-2018026782-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376250-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | OPRL1 27/4885OPRM1 35/4885OPRD1 38/4885 |
| US-20190175588-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | OPRL1 27/4885OPRM1 35/4885OPRD1 38/4885 |
| US-20210322406-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | OPRL1 27/4885OPRM1 35/4885OPRD1 38/4885 |
| US-10918637-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | OPRL1 27/4885OPRM1 35/4885OPRD1 38/4885 |
| US-20230210851-A1 | SPIRO-LACTAM COMPOUNDS AND METHODS OF TREATING VIRAL INFECTIONS USING THE SAME | ACE, ACE2, PREP | OPRL1 1783/4885OPRM1 2893/4885OPRD1 2074/4885 |
| US-20220273629-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH ELEVATED LEVELS OF ANTIBODIES THAT INTERACT WITH THE NMDA RECEPTOR | GRIN2A, GRIN2B, GRIN1 | OPRL1 55/4885OPRM1 353/4885OPRD1 150/4885 |
| US-20230131402-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | OPRL1 27/4885OPRM1 35/4885OPRD1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.